WO2016147197A1 - A novel process for preparing (2s,3r,4r,5s,6r)-2-[4-chloro-3-(4-ethoxybenzyl)pheny 1] -6-(hy droxy methyl)tetrahydro-2h-py ran-3,4,5-triol and its amorphous form - Google Patents

A novel process for preparing (2s,3r,4r,5s,6r)-2-[4-chloro-3-(4-ethoxybenzyl)pheny 1] -6-(hy droxy methyl)tetrahydro-2h-py ran-3,4,5-triol and its amorphous form Download PDF

Info

Publication number
WO2016147197A1
WO2016147197A1 PCT/IN2015/000334 IN2015000334W WO2016147197A1 WO 2016147197 A1 WO2016147197 A1 WO 2016147197A1 IN 2015000334 W IN2015000334 W IN 2015000334W WO 2016147197 A1 WO2016147197 A1 WO 2016147197A1
Authority
WO
WIPO (PCT)
Prior art keywords
chloro
tetrahydro
pyran
phenyl
triol
Prior art date
Application number
PCT/IN2015/000334
Other languages
French (fr)
Inventor
Vijay Trimbak KADAM
Saikrishna
Tukaram Sarjerao CHOUDHARE
Harpreet Singh Minhas
Gurpreet Singh Minhas
Original Assignee
Harman Finochem Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harman Finochem Limited filed Critical Harman Finochem Limited
Publication of WO2016147197A1 publication Critical patent/WO2016147197A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms

Definitions

  • the present invention relates to an industrially feasible process for preparation of (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro- 2H-pyran-3 ,4, 5 -triol .
  • (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro- 2H-pyran-3,4,5-triol is sodium dependent glucose transporter (SGLT) which is currently under investigation for the treatment of type-2 diabetes.
  • (2S,3R,4R,5S,6R)-2-[4-chloro-3- (4-ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol is marketed under the tradename Farxiga or Forxiga.
  • (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro- 2H-pyran-3,4,5-triol is also known as D-glucitol, l,5-anhydro-l-C-[4-chloro-3- [(4ethoxyphenyl)methyl]phenyl]-, (I S).
  • (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4- ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro-2H-pyran-3, 4,5 -triol is a white to off-white powder with a molecular formula of C2iH2 5 C10 6 and a molecular weight of 408.87
  • This compound reacts with acetic anhydride in presence of THF, DIPEA and DMAP to get oily residue of methyl-2,3,4,6 tetra-0-acetyl-l-C-(2-chloro-4'- ethoxydiphenylmethan-3-yl)-a-D-glucopyranose which further undergoes reduction reaction in presence of acetonitirle, t riethylsilane, boron trifluoride etherate to yield 2,3,4,6-tetra-0-acetyl-l-C-(2-chloro-4'-ethoxydi henylmethan-3-yl)- ⁇ -D-glucopyranose which is further deprotected by reacting with LiOH monohydrate in presence of THF/MeOH/H 2 0 to get (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxybenzyl)phenyl]-6- (hydroxymethyl
  • the said prior art describes multiple, time consuming process steps which involves getting the intermediate products as oily residue at various stages of the process, which is difficult to purify and handle for further process step. More over the workup involves multiple evaporation of product which may result in decomposition.
  • Another drawback of the process is that the process describes n-BuLi reaction with two pot reaction. It is very difficult to transfer the material from one reactor to second reactor at -78 °C at industrial level with highly moisture sensitive reaction mass. This makes process uneconomical, cumbersome and commercially not viable.
  • WO 2008002824 A 1 discloses crystalline forms of (2S,3R,4R,5S,6R)-2-[4-chloro-3- (4-ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol comprising (S)-propylene glycol (PG), (R)-PG, EtOH, ethylene glycol (EG), 1 :2 L-proline, 1 : 1 L- proline, 1 : 1 L-proline hemihydrate, 1 : 1 L-phenylalanine and its preparation process.
  • the present invention provides the process for preparation of (2S,3R,4R,5S,6R)-2-[4- chloro-3 -(4-ethoxybenzyl)phenyl] -6-(hydroxymethyl)tetrahydro-2H-pyran-3 ,4,5 - triol(Formula-I) and its stable amor hous form.
  • the present invention describes the silylation process for preparing 3,4,5- Tris-trimethylsilanyloxy-6-trimethylsilanyloxymethyl-tetrahydro-pyran-2-one from 3 ,4,5 - Trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-one which comprises;
  • the present invention discloses the process for preparing 2-R 1 -2-[4- chloro-3-(4-ethoxy-benzyl)-phenyl]-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol from 3,4,5-Tris-trimethylsilanyloxy-6-trimethylsilanyloxymethyl-tetrahydro-pyran-2-one which comprises;
  • the present invention describes process for preparing (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro- 2H-pyran-3,4,5-triol by reduction of 2-R 1 -2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6- hydroxymethyl-tetrahydro-pyran-3,4,5-triol which comprises;
  • the instant invention provides process for preparing stable amorphous form of (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxybenzyl)phenyl]-6- (hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol from (2S,3R,4R,5S,6R)-2-[4-chloro-3- (4-ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol which comprises;
  • the present invention describes the process for preparing amorphous form of (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxybenzyl)phenyl]-6- (hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol from L-proline complex of (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro- 2H-pyran-3,4,5-triol which comprises;
  • the present process gives a-Isomer in the range of 3-5 %., which is removed during purification; further, the Des-bromoimpuirity (2-chloro -4'- ethoxydiphenylmethane) formation is restricted to 3-4 % during purification. Further work up disclosed in present invention is advantageous over the teachings of prior art as the purification process does not involve multiple step workup. The purification process simply carried out with solvents which is commercially feasible.
  • the instant invention provides an efficient, advantageous and economical process for preparing (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxybeiizyl)phenyl]-6- (hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (Formula-I) and its amorphous form.
  • the present invention describes the silylation process for preparing 3,4,5-Tris-trimethylsilanyloxy-6-trimethylsilanyloxymethyl-tetrahydro-pyran-2-one from 3,4,5-Trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-one which comprises;
  • solvent' refers to polar aprotic solvents selected from the group consisting of tetrahydrofuran, ethyl acetate, acetone, dimethylformamide, acetonitrile, dimethyl sulfoxide.
  • the organic base is selected from the group consisting, of triethylamine, diisopropyl ethylamine, N-methyl morpholine& N-methyl pyrrolidine.
  • the reaction is carried out at -5 to 0°C.
  • the instant invention discloses the process for preparing 2-R'-2- [4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol from 3,4,5-Tris-trimethylsilanyloxy-6-trimethylsilanyloxymethyl-tetrahydro-pyran-2-one which comprises;
  • the polar aprotic solvent is selected from the group consisting of tetrahydrofuran, ethyl acetate, acetone, dimethylformamide, acetonitrile, dimethyl sulfoxide.
  • the non-polar solvent is selected from the group consisting of Toluene, Hexane, 1,4-Dioxane, Chloroform, Diethyl ether, Dichloromethane.
  • reaction temperature is -70 to -80 °C.
  • Organolithium reagent' refers to alkyllithium reagents selected from the group consisting of n-butyl lithium, methyl lithium, t-butyl lithium.
  • alkyl sulfonic acid refers to methane sulfonic acid.
  • the unsaturated aliphatic alcohol is selected from the group consisting of allyl alcohol, isopropyl alcohol or propargyl alcohol.
  • the present process gives a- Isomer in the range of 3-4 %., which is removed during purification, Des-bromoimpuirity (2-chloro -4'- ethoxydiphenylmethane) formation is restricted to 3-5 %during purification.
  • R 1 is allyl, prop-2ynyl.
  • the invention encompasses the compound 2-R 1 -2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6- hydroxymethyl-tetrahydro-pyran-3,4,5-triol of formula V.
  • R 1 is allyl, prop-2ynyl.
  • the invention encompasses the novel intermediate compounds (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydn 2H-pyran-3,4,5-triol, viz., (a) 2-Allyloxy-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-hydroxymethyl-tetrahydro- pyran-3,4,5-triol
  • novel intermediates are having better leaving groups- allyl, propargyl as compare to hydroxyl, alkyl which increases reaction rate and gives higher yield with reduced reaction time.
  • the instant invention discloses process for preparing des-bromo (4-(5-2-chlorobenzyl) phenyl ethyl ether) impurity which comprises;
  • the alkyl lithiums is selected from the group consisting of n-butyl lithium, methyl lithium, t-butyl lithium.
  • the polar aprotic solvent is selected from the group consisting of tetrahydrofuran, ethyl acetate, acetone, dimethylformamide, acetonitrile, dimethyl " sulfoxide.
  • the non-polar solvent is selected from the group consisting of Toluene, Hexane, 1,4-Dioxane, Chloroform, Diethyl ether, Dichloromethane. According to above process the reaction temperature is -70 to -80°C.
  • the main object is achieved by removing the des-bromo impurity during the purification of 2-2-R 1 -2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-hydroxymethyl-tetrahydro-pyran- 3,4,5-triol, without involving any special techniques, that makes the process less cumbersome and cost-effective.
  • the present invention describes process for preparing (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro- 2H-pyran-3,4,5-triol by reduction of 2-R 1 -2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6- hydroxymethyl-tetrahydro-pyran-3,4,5-triol which comprises;
  • Organosilane' refers to alkylsilane or polyalkylsilane is selected from the group consisting of trimethylsilane, triethylsilane, tetramethylsilane, dimethylsilane.
  • the non-polar solvent is selected from the group consisting of Dichloromethane, Toluene, Hexane, 1 ,4-Dioxane, Chloroform, Diethyl ether and the polar aprotic solvent is selected from the group consisting of acetonitrile, tetrahydrofuran, ethyl acetate, acetone, dimethylformamide, dimethyl sulfoxide.
  • the acid for the above said process is selected from the group consisting of borontrifluoride in diethylether, trifluoroacetic acid, methanesulfonic acid.
  • R 1 is allyl, prop-2ynyl.
  • the instant invention provides process for preparing stable amorphous form of (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxybenzyl)phenyl]-6- (hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol from (2S,3R,4R,5S,6R)-2 7 [4-chloro-3- (4-ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol which comprises;
  • the non-polar solvent for said process is selected from the group consisting of n-Heptane, Dichloromethane, Toluene, Hexane, 1,4-Dioxane, Chloroform, Diethyl ether.
  • the ambient temperature is 25-30 °C.
  • the other object of the present invention is to get stable amorphous form of (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro- 2H-pyran-3,4,5-triol which is achieved without using any special technique which makes the process simple, cost- effective and time saving.
  • the present invention describes the preparation of L-proline complex of (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxybenzyl)phenyl]-6-
  • the polar aprotic solvent for above said process is selected from the group consisting of ethyl acetate, acetone, acetonitrile, tetrahydrofuran, dimethylformamide,. dimethyl sulfoxide and the non-polar solvent is selected from the group consisting of n-Heptane, Dichloromethane, Toluene, Hexane, 1,4-Dioxane, Chloroform, Diethyl ether.
  • the temperature for the above said process is 60-65 °C.
  • the present invention describes the process for preparing amorphous form of (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxybenzyl)phenyl]-6- (hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol from L-proline complex of (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro- 2H-pyran-3,4,5-triol which comprises;
  • Example-2 Preparation of 2-Allyloxy-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6- hydroxymethyI-tetrahydro-pyran-3,4,5-triol
  • reaction mass was quenched with Methane sulphonic acid and Allyl alcohol mixture at -70 to -80°C. Temperature was raised to ambient temperature and stirred overnight. Reaction mass was quenched with 30 cc sat.sodiumbicarbonate solution to bring the pH neutral to alkaline and stirred for 30.0 min. Layers separated and aqueous layer was extracted with 10 cc of Toluene.
  • Aromatic C C stretching: 1510 , 1548 , 1603 , 1703 cm "1
  • Aromatic C C stretching: 1510 , 1548 , 1603 , 1703 cm "1
  • Example 7 Preparation of amorphous form of (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4- ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol

Abstract

The present invention discloses the process for preparation of (2S,3R,4R,5S,6R)-2-[4- chloro-3-(4-ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol and its amorphous form.

Description

"A novel process for preparing (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4- ethoxybenzyl)pheny 1] -6-(hy droxy methyl)tetrahydro-2H-py ran-3,4,5-triol and its amorphous form"
FIELD OF INVENTION:
The present invention relates to an industrially feasible process for preparation of (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro- 2H-pyran-3 ,4, 5 -triol .
BACKGROUND OF INVENTION:
(2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro- 2H-pyran-3,4,5-triol is sodium dependent glucose transporter (SGLT) which is currently under investigation for the treatment of type-2 diabetes. (2S,3R,4R,5S,6R)-2-[4-chloro-3- (4-ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol is marketed under the tradename Farxiga or Forxiga.
(2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro- 2H-pyran-3,4,5-triol is also known as D-glucitol, l,5-anhydro-l-C-[4-chloro-3- [(4ethoxyphenyl)methyl]phenyl]-, (I S). (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4- ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro-2H-pyran-3, 4,5 -triol is a white to off-white powder with a molecular formula of C2iH25C106 and a molecular weight of 408.87
Figure imgf000002_0001
Formula-I
US 6,515,117 B2 discloses (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxybenzyl)phenyl]-6- (hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol and its pharmaceutically acceptable salts. US 6,515,117 B2 also describes process for preparation of (2S,3R,4R,5S,6R)-2-[4- chloro-3-(4-ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol which comprises reaction of 5-bromo-2-chloro-4'-ethoxydiphenylmethane with 2,3,4,6- tetra-O-trimethylsilyl- -D-glucolactone in presence of THF/Toluene, methansulfonic acid to yield o-methylglucoside product which further reacts with Et3SiH, BF3Et20 in presence of MDC and acetonitrile to yield yellow solidified foam which is dissolved in MDC, pyridine and followed by acetylation with acetic anhydride, DMAP to yield tetra acetylated- β-C-glucoside as a white solid which is further deprotected with LiOH H20 in presence of THF/MeOH/H20 to get (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4- ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol.
The drawback of said prior art is having multiple process steps which makes the process very lengthy and tedious. Moreover the process discloses use of hazardous chemicals like pyridine which is not applicable to industry.
Process for preparation of (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxybenzyl)phenylJ- 6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol is disclosed in US 7,375,213 B2 and J.Med.Chem.2008, 51, 1145-1149. The preparation process is depicted in Scheme-I.
Figure imgf000003_0001
Scheme-1
Prior art US'213 describes reaction of 2-chloro-5-bromo-4'-ethoxy-diphenylmethane with 2,3,4,6-tetra-O-trimethylsilyl-D-gluconolactone, n-BuLi in presence of THF and Heptane. After basification with TEA, the oily residue of methyl- l-C-(2-chloro-4'- ethoxy-diphenylmethan-3-yl)-a-D-glucopyranose obtained as solid compound after workup. This compound reacts with acetic anhydride in presence of THF, DIPEA and DMAP to get oily residue of methyl-2,3,4,6 tetra-0-acetyl-l-C-(2-chloro-4'- ethoxydiphenylmethan-3-yl)-a-D-glucopyranose which further undergoes reduction reaction in presence of acetonitirle, t riethylsilane, boron trifluoride etherate to yield 2,3,4,6-tetra-0-acetyl-l-C-(2-chloro-4'-ethoxydi henylmethan-3-yl)-β-D-glucopyranose which is further deprotected by reacting with LiOH monohydrate in presence of THF/MeOH/H20 to get (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxybenzyl)phenyl]-6- (hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol.
The said prior art describes multiple, time consuming process steps which involves getting the intermediate products as oily residue at various stages of the process, which is difficult to purify and handle for further process step. More over the workup involves multiple evaporation of product which may result in decomposition. Another drawback of the process is that the process describes n-BuLi reaction with two pot reaction. It is very difficult to transfer the material from one reactor to second reactor at -78 °C at industrial level with highly moisture sensitive reaction mass. This makes process uneconomical, cumbersome and commercially not viable. Further when practically the said method followed, a-Isomer of the final product is formed in the range of 6-8% along ith Des- bromo impurity formed in the range of 7-9 %, which increases after addition of n- butyllithium and kept the mass for overnight reaction. Moreover lactone ring cleavage is also observed in the range of 3-4% after addition of Methanesulphonic Acid/Methanol and maintained overnight for reaction completion, the removal of which is difficult from the final product.
WO 2008002824 A 1 discloses crystalline forms of (2S,3R,4R,5S,6R)-2-[4-chloro-3- (4-ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol comprising (S)-propylene glycol (PG), (R)-PG, EtOH, ethylene glycol (EG), 1 :2 L-proline, 1 : 1 L- proline, 1 : 1 L-proline hemihydrate, 1 : 1 L-phenylalanine and its preparation process.
In the light of the above drawbacks, it is necessitated to provide economical, robust, safe and commercially viable process for preparing (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4- ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol. Accordingly, it is an objective of the present invention to provide a commercially viable process for the preparation of (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4- ethoxyb.enzyl)phenyl]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol, prepared via riovel intermediates which gives higher yield and purity and facilitates easy recovery of the final compound. The purification process does not involve any costly technique/equipment, however, carried out with solvents which are industrially feasible. More over the present invention discloses the n-BuLi insitu reaction that makes the present invention cost-effective over the teachings of prior art.
SUMMARY OF THE INVENTION:
The present invention provides the process for preparation of (2S,3R,4R,5S,6R)-2-[4- chloro-3 -(4-ethoxybenzyl)phenyl] -6-(hydroxymethyl)tetrahydro-2H-pyran-3 ,4,5 - triol(Formula-I) and its stable amor hous form.
Figure imgf000005_0001
Formula-
In one aspect, the present invention describes the silylation process for preparing 3,4,5- Tris-trimethylsilanyloxy-6-trimethylsilanyloxymethyl-tetrahydro-pyran-2-one from 3 ,4,5 - Trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-one which comprises;
(a) Reacting 3,4,5-Trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-one with trimethyl silyl chloride in presence of solvent and organic base at ambient temperature;
(b) Maintaining pH 7-8 by adding sat. sodium bicarbonate; and
(c) Separating organic layer followed by distillation to isolate 3,4,5-Tris- trimethylsilanyloxy-6-trimethylsilanyloxymethyl-tetrahydro-pyran-2-one.
In another aspect, the present invention discloses the process for preparing 2-R1-2-[4- chloro-3-(4-ethoxy-benzyl)-phenyl]-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol from 3,4,5-Tris-trimethylsilanyloxy-6-trimethylsilanyloxymethyl-tetrahydro-pyran-2-one which comprises;
(a) Reacting 4-(5-bromo-2-chlorobenzyl)phenyl ethyl ether with 3,4,5-Tris- trimethylsilanyloxy-6-trimethylsilanyloxymethyl-tetrahydro-pyran-2-one in presence of mixture of polar aprotic solvent and non-polar solvent, organolithium reagent, alkyl sulfonic acid, monohydric or unsaturated aliphatic alcohol;
(b) Bringing pH from neutral to alkaline;and
(c) Separating organic layer to isolate 2-R'-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]- 6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol.
In another embodiment, the present invention describes process for preparing (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro- 2H-pyran-3,4,5-triol by reduction of 2-R1-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6- hydroxymethyl-tetrahydro-pyran-3,4,5-triol which comprises;
(a) Reacting 2-R'-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-hydroxymethyl- tetrahydro-pyran-3,4,5-triol with organosilane in presence of acid, mixture of non-polar solvent and polar aprotic solvent under argon atmosphere;
(b) Quenching with sat. sodium bicarbonate solution; and
(c) Separating layers to isolate (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4- ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol.
In another embodiment, the instant invention provides process for preparing stable amorphous form of (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxybenzyl)phenyl]-6- (hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol from (2S,3R,4R,5S,6R)-2-[4-chloro-3- (4-ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol which comprises;
(a) Stirring (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxybenzyl)phenyl]-6- (hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol with non-polar solvent at ambient temperature and
(b) Isolating amorphous form of (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4- ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol. In another embodiment, the present invention describes the preparation of L-proline complex of (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxybenzyl)phenyl]-6-
(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol from (2S,3R,4R,5S,6R)-2-[4-chloro-3- (4-ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol which comprises;
(a) Reacting (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxybenzyl)phenyl]-6- (hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol with proline in presence of polar aprotic solvent under argon atmosphere;
(b) Adding non-polar solvent and
(c) Isolating L-proline complex of (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4- ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro-.2H-pyran-3,4,5-triol.
In another embodiment, the present invention describes the process for preparing amorphous form of (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxybenzyl)phenyl]-6- (hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol from L-proline complex of (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro- 2H-pyran-3,4,5-triol which comprises;
(a) Stirring L-proline complex of , (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4- ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol in presence of ethyl acetate;
(b) Adding sat. sodium bicarbonate solution;
(c) Adding n-Heptane and
(d) Isolating stable amorphous form of (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4- ethoxybenzyl)phenyl] -6-(hydroxymethyl)tetrahydro-2H-pyran-3 ,4,5 -triol.
The present process gives a-Isomer in the range of 3-5 %., which is removed during purification; further, the Des-bromoimpuirity (2-chloro -4'- ethoxydiphenylmethane) formation is restricted to 3-4 % during purification. Further work up disclosed in present invention is advantageous over the teachings of prior art as the purification process does not involve multiple step workup. The purification process simply carried out with solvents which is commercially feasible. Thus the instant invention provides time saving, cost effective and commercially viable process for preparing (2S,3R,4R,5S,6R)-2-[4- chloro-3-(4-ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol. DETAILED DESCRIPTION OF THE INVENTION:
The instant invention provides an efficient, advantageous and economical process for preparing (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxybeiizyl)phenyl]-6- (hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (Formula-I) and its amorphous form.
Figure imgf000008_0001
Formula-I
In one embodiment, the present invention describes the silylation process for preparing 3,4,5-Tris-trimethylsilanyloxy-6-trimethylsilanyloxymethyl-tetrahydro-pyran-2-one from 3,4,5-Trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-one which comprises;
(a) Reacting 3,4,5-Trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-one with trimethyl silyl chloride in presence of solvent and organic base at ambient temperature;
(b) Maintaining pH 7-8 by adding sat. sodium bicarbonate;
(c) Separating organic layer followed by distillation to isolate 3,4,5-Tris- trimethylsilanyloxy-6-trimethylsilanyloxymethyl-tetrahydro-pyran-2-one.
The process for preparing 3,4,5-Tris-trimethylsilanyloxy-6-trimethylsilanyloxymethyl- tetrahydro-pyran-2-one depicted in the following reaction Scheme II.
Figure imgf000008_0002
Scheme-II The term 'solvent' refers to polar aprotic solvents selected from the group consisting of tetrahydrofuran, ethyl acetate, acetone, dimethylformamide, acetonitrile, dimethyl sulfoxide. The organic base is selected from the group consisting, of triethylamine, diisopropyl ethylamine, N-methyl morpholine& N-methyl pyrrolidine.
According to above process, the reaction is carried out at -5 to 0°C.
In another embodiment, the instant invention discloses the process for preparing 2-R'-2- [4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol from 3,4,5-Tris-trimethylsilanyloxy-6-trimethylsilanyloxymethyl-tetrahydro-pyran-2-one which comprises;
(a) Reacting > 4-(5-bromo-2-chlorobenzyl)phenyl ethyl ether with 3,4,5-Tris- trimethylsilanyloxy-6-trimethylsilanyloxymethyl-tetrahydro-pyran-2-one in presence of mixture of polar aprotic solvent and non-polar solvent, organolithium reagent, alkyl sulfonic acid, monohydric or unsaturated aliphatic alcohol;
(b) Bringing pH neutral to alkaline;
(c) Separating organic layer to isolate 2-R1-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]- 6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol.
The reaction scheme for preparing 2-R1-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6- hydroxymethyl-tetrahydro-pyran-3,4,5-triol is given in Scheme III.
Figure imgf000009_0001
Formula-Ill Formula-IV
Formula-V where R1= allyl, prop-2-ynyl,isopropyl
Scheme-Ill In the above said process, the polar aprotic solvent is selected from the group consisting of tetrahydrofuran, ethyl acetate, acetone, dimethylformamide, acetonitrile, dimethyl sulfoxide. The non-polar solvent is selected from the group consisting of Toluene, Hexane, 1,4-Dioxane, Chloroform, Diethyl ether, Dichloromethane.
According to above process the reaction temperature is -70 to -80 °C.
The term Organolithium reagent' refers to alkyllithium reagents selected from the group consisting of n-butyl lithium, methyl lithium, t-butyl lithium. The term alkyl sulfonic acid refers to methane sulfonic acid. The unsaturated aliphatic alcohol is selected from the group consisting of allyl alcohol, isopropyl alcohol or propargyl alcohol.
The present process gives a- Isomer in the range of 3-4 %., which is removed during purification, Des-bromoimpuirity (2-chloro -4'- ethoxydiphenylmethane) formation is restricted to 3-5 %during purification.
In above process R1 is allyl, prop-2ynyl.
The main advantage of above said process is deprotection step which undergoes insitu simultaneously. Therefore additional and multiple steps/ work up can be avoided which results in economical, time saving and safe process. Accordingly, the invention encompasses the compound 2-R1-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6- hydroxymethyl-tetrahydro-pyran-3,4,5-triol of formula V.
Figure imgf000010_0001
wherein, R1 is allyl, prop-2ynyl.
Formula-V
Therefore, the invention encompasses the novel intermediate compounds (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydn 2H-pyran-3,4,5-triol, viz., (a) 2-Allyloxy-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-hydroxymethyl-tetrahydro- pyran-3,4,5-triol
(b) 2-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-6-hydroxyniethyl-2-prop-2-ynyloxy- tetrahydro-pyran-3,4,5-triol.
The novel intermediates are having better leaving groups- allyl, propargyl as compare to hydroxyl, alkyl which increases reaction rate and gives higher yield with reduced reaction time.
, In another embodiment the instant invention discloses process for preparing des-bromo (4-(5-2-chlorobenzyl) phenyl ethyl ether) impurity which comprises;
(a) Reacting 4-(5-bromo-2-chlorobenzyl) phenyl ethyl ether with alkyllithium in presence of mixture of polar aprotic solvent and non-polar solvent;
(b) Adding ammonium chloride solution and
(c) Isolating 2-chloro -4'- ethoxydiphenylmethane.
The alkyl lithiums is selected from the group consisting of n-butyl lithium, methyl lithium, t-butyl lithium. The polar aprotic solvent is selected from the group consisting of tetrahydrofuran, ethyl acetate, acetone, dimethylformamide, acetonitrile, dimethyl " sulfoxide. The non-polar solvent is selected from the group consisting of Toluene, Hexane, 1,4-Dioxane, Chloroform, Diethyl ether, Dichloromethane. According to above process the reaction temperature is -70 to -80°C.
The main object is achieved by removing the des-bromo impurity during the purification of 2-2-R1-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-hydroxymethyl-tetrahydro-pyran- 3,4,5-triol, without involving any special techniques, that makes the process less cumbersome and cost-effective.
In another embodiment the present invention describes process for preparing (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro- 2H-pyran-3,4,5-triol by reduction of 2-R1-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6- hydroxymethyl-tetrahydro-pyran-3,4,5-triol which comprises;
(a) Reacting 2-R'-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-hydroxymethyl- tetrahydro-pyran-3,4,5-triol with organosilane in presence of acid, mixture of non-polar solvent and polar aprotic solvent under argon atmosphere; (b) Quenching with sat. sodium bicarbonate solution;
(c) Separating layers and
(d) Isolating (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxybenzyl)phenyl]-6- (hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol.
The reaction scheme for said process is given in Scheme-IV.
Figure imgf000012_0001
where R = allyl, prop-2-ynyl
Scheme-IV
According to above said process the term Organosilane' refers to alkylsilane or polyalkylsilane is selected from the group consisting of trimethylsilane, triethylsilane, tetramethylsilane, dimethylsilane. The non-polar solvent is selected from the group consisting of Dichloromethane, Toluene, Hexane, 1 ,4-Dioxane, Chloroform, Diethyl ether and the polar aprotic solvent is selected from the group consisting of acetonitrile, tetrahydrofuran, ethyl acetate, acetone, dimethylformamide, dimethyl sulfoxide. The acid for the above said process is selected from the group consisting of borontrifluoride in diethylether, trifluoroacetic acid, methanesulfonic acid.
The above reaction is carried out at -40 to 55 °C.
In above process R1 is allyl, prop-2ynyl.
In one another embodiment the instant invention provides process for preparing stable amorphous form of (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxybenzyl)phenyl]-6- (hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol from (2S,3R,4R,5S,6R)-27[4-chloro-3- (4-ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol which comprises;
) (a) Stirring (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxybenzyl)phenyl]-6- (hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol with non-polar solvent at ambient temperature and
(b) Isolating stable amorphous form of (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4- ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol.
The non-polar solvent for said process is selected from the group consisting of n-Heptane, Dichloromethane, Toluene, Hexane, 1,4-Dioxane, Chloroform, Diethyl ether. The ambient temperature is 25-30 °C.
The other object of the present invention is to get stable amorphous form of (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro- 2H-pyran-3,4,5-triol which is achieved without using any special technique which makes the process simple, cost- effective and time saving.
In another embodiment the present invention describes the preparation of L-proline complex of (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxybenzyl)phenyl]-6-
(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol from (2S,3R,4R,5S,6R)-2-[4-chloro-3- (4-ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol which comprises;
(a) Reacting (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxybenzyl)phenyl]-6- (hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol with L-proline in presence of polar aprotic solvent under argon atmosphere;
(b) Adding non-polar solvent and
(c) Isolating L-proline complex of (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4- ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol.
The reaction scheme for said process is given in Scheme-V.
Figure imgf000014_0001
Scheme-V
The polar aprotic solvent for above said process is selected from the group consisting of ethyl acetate, acetone, acetonitrile, tetrahydrofuran, dimethylformamide,. dimethyl sulfoxide and the non-polar solvent is selected from the group consisting of n-Heptane, Dichloromethane, Toluene, Hexane, 1,4-Dioxane, Chloroform, Diethyl ether. The temperature for the above said process is 60-65 °C.
In another embodiment the present invention describes the process for preparing amorphous form of (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxybenzyl)phenyl]-6- (hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol from L-proline complex of (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro- 2H-pyran-3,4,5-triol which comprises;
(a) Stirring L-proline complex of (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4- ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol in presence of ethyl acetate;
(b) Adding sat. sodium bicarbonate solution;
(c) Adding n-Heptane and
(d) Isolating stable amorphous form of (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4- ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
The following examples, which include preferred embodiments, will serve to illustrate the practice of this invention, it being understood that the particulars shown are by way of example and for purpose of illustrative discussion of preferred embodiments of the invention. Examples:
Example-1: Preparation of 3,4,5-Tris-trimethylsiIanyloxy-6- trimethylsiIanyloxymethyl-tetrahydro-pyran-2-one
To 750 cc of dry THF added 1.12 mole 3,4,5-Trihydroxy-6-hydroxymethyl-tetrahydro- pyran-2-one at ambient temperature and stirred for 20 min. To the reaction mass added 9.0 mole N-Methyl morpholine and stirred for another 30.0 min at ambient temperature. Reaction mass was cooled to -5 °C to 0 °C and stirred for 30.0 min. Added 18.0 mole Trimethyl sillyl chloride at the temp -5 °C to 0 °C and stirred for 30.0 min. Temperature was raised to 25 °C to 30 °C and maintained for 18-20hrs. After reaction complies by GC, the reaction mass was cooled to -5 deg to 0 deg. Added Sat.Sodium bicarbonate solution to obtain the pH 7-8 and stirred for 1 hr at 0 °C. Added 500 cc toluene and stirred for lhr. Reaction mass was settled down for 30.0 min and layers were separated. To the Aqueous layer added 250 cc of toluene and stirred for 30.0 min. Layers separated and both the organic layers mixed and back washed with sat.brine solution. Organic layer was distilled under reduced pressure at a temperature of about 40 - 48 deg. Unload the oily mass . Purity: 92-96 %
Example-2: Preparation of 2-Allyloxy-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6- hydroxymethyI-tetrahydro-pyran-3,4,5-triol
To the mixture of 10 cc THF and 10 cc Toluene added 0.138 mole 4-(5-bromo-2- chlorobenzyl)phenyl ethyl ether at ambient temperature and stirred for 15 min. Cooled to -70 to -80°C in dry ice /acetone bath and stirred for 15 min. Added a solution of 0.014 mole n-Butyl lithium (1.9M in hexanes) at -70 to -80°C. and stirred for lhr. Added solution of 3, 4, 5-Tris-trimethylsilanyloxy-6-trimethylsilanyloxymethyl-tetrahydro- pyran-2-one in 5 cc of Toluene at -70 to -80°C and stirred for 2 to 3hrs. After the compliance of the reaction, reaction mass was quenched with Methane sulphonic acid and Allyl alcohol mixture at -70 to -80°C. Temperature was raised to ambient temperature and stirred overnight. Reaction mass was quenched with 30 cc sat.sodiumbicarbonate solution to bring the pH neutral to alkaline and stirred for 30.0 min. Layers separated and aqueous layer was extracted with 10 cc of Toluene. Organic layer was combined and washed with 30cc water and 50 cc sat. brine solution. Organic layer was distilled under reduced pressure to recover toluene. Solid compound was dissolved in 50cc of toluene and quenched in n-Hexane to obtain 83 % the compound as crystalline solid. HPLC purity: 88 - 91 %
I R data:
Anomeric C-0 stretching: 1242 cm"1
Allylic C- O stretching: 1 177 cm"1
Allylic C- H stretching: 3010 - 3120 cm"1
Aromatic C- CI stretching: 820 cm"1
Lactones O - H stretching: 3240 - 3380 cm"1
Lactones C - 0 stretching: 1045 - 1092 cm"1
Aromatic C=C stretching: 1510 , 1548 , 1603 , 1703 cm"1
Alkane C - H stretching: 2877,2866, 2956, 2958, 2962 cm"1
Aromatic C - H stretching: 3050 - 3090 cm"1
Dip-Mass
(M+Na) 487.19 m/z
(M+K) 503.17 m/z
Example 3: Preparation of 2-prop-2ynyl-2-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-6- hydroxymethyl-tetrahydro-pyran-3,4,5-triol
To the mixture of 10 cc THF and 10 cc Toluene added 0.138 mole 4-(5-bromo-2- chlorobenzyl)phenyl ethyl ether at ambient temperature and stirred for 15 min. Cooled to -70 to -80°C in dry ice /acetone bath and stirred for 15 min. Added a solution of 0.014 mole n-Butyl lithium (1.9M in hexanes) at -70 to -80°C. and stirred for lhr. Added solution of 3, 4, 5-Tris-trimethylsilanyloxy-6-trimethylsilanyloxymethyl-tetrahydro- pyran-2-one in 5 cc of Toluene at -70 to -80°C and stirred for 2 to 3hrs. After the compliance of the reaction, the reaction mass was quenched with Methane sulphonic acid and propargyl alcohol mixture at -70 to -80°C. Temperature was raised to ambient temperature and stirred overnight. Reaction mass was quenched with 30 cc sat.sodiumbicarbonate solution to bring the pH neutral to alkaline. Reaction mass stirred for 30.0 min. Layers separated and aqueous layer was extracted with 10 cc of Toluene. Organic layer were combined and washed with 30cc water and 50 cc sat. brine solution. Organic layer was distilled under reduced pressure to recover toluene. Solid compound dissolved in 50cc of toluene and quenched in n-Hexane to obtain 75 - 80 % the compound as crystalline solid.
HPLC purity: 88 - 93 %
IR data: Anomeric C-0 stretching: 1242 cm"1
Propargyl ~c CH stretching: 2125 cm"1
Propargyl C- H stretching : 3010 - 3120 cm"1
Aromatic C- CI stretching: 820 cm"1
Lactones O - H stretching: 3240 - 3380 cm"1
Lactones C - 0 stretching: 1045 - 1092 cm"1
Aromatic C=C stretching: 1510 , 1548 , 1603 , 1703 cm"1
Alkane C - H stretching: 2877, 2866,2956,2958,2962 cm"1
Aromatic C - H stretching: 3050 - 3090 cm"1
Dip-Mass
(M+Na) 485.25 m/z
(M+K) 501.25 m/z
Example-4: Preparation of 2-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-6- hydroxymethyI-tetrahydro-pyran-3,4,5-trioI
To the mixture of 20 cc (1 : 1 MDC + ACN) added 0.1 1 mole 2-Allyloxy-2-[4-chloro-3-(4- ethoxy-benzyl)-phenyl]-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol under argon atmosphere, and stirred the reaction mass for 30.0 min. Cooled the reaction mass to -40 to -55°C in a dry ice/acetone bath under argon atmosphere. Charged 3 mole Triethylsilane at -40 to -55°C and stirred the reaction mass for 30.0 min at -50 to -55°C. Slowly added Borontrifloride in diethyl ether solution at -40 to -55°C and stirred the reaction mass for 2 hrs. Quenched the reaction mass with 50 cc sat. sodium bicarbonate solution at -40 to - 55°C . and stirred the reaction mass for 30.0 min. Slowly raised the temperature to 25 to 30°C. Settled down the reaction mass and separated the layers, extracted the aqueous layer with 100 cc of MDC. Combined the organic layer and wash with 500 cc water. Washed the organic layer with 500 cc of sat. Brine solution. Distilled out the MDC under reduced pressure below 40°C. to get 85 %the light yellow solid.
HPLC purity: 92-95 %
Example 5: Preparation of 2-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-6- hydroxymethyl-tetrahydro-pyran-3,4,5-triol
To the mixture of 20 cc (1 :1 MDC + ACN) added 0.11 mole 2-prop-2-ynyl-2-[4-Chloro- 3-(4-ethoxy-benzyl)-phenyl]-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol under argon atmosphere. Stirred the reaction mass for 30.0 min. Cooled the reaction mass to -40 to - 55°C in a dry ice/acetone bath under argon atmosphere. Charged 3 mole Triethylsilane at -40 to -55°C and stirred the reaction mass for 30.0 min at -50 to -55°C. Slowly added Borontrifloride in diethyl ether solution at -40 to -55°C and stirred the reaction mass for 2 hrs. Quenched the reaction mass with 50 cc sat. sodium bicarbonate solution at -40 to - 55°C and Stirred the reaction mass for 30.0 min. Slowly raised the temperature to 25 to 30°C. Settled down the reaction mass and separated the layers, extracted the aqueous layer with 100 cc of MDC. Combined the organic layer and washed with 500 cc water. Washed the organic layer with 500 cc of sat. Brine solution. Distilled out the MDC under reduced pressure below 40°C. to get 85%the light yellow solid.
HPLC purity: 90%
Example 6: Preparation of amorphous form of (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4- ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
To the solid obtained from example 4 charged 500cc of n-heptane and stirred for ½hrs at ambient temperature. Heated the reaction mass to 55-60°C and stirred it for 2-3 hrs.; cooled to room temperature and maintained for 4-5 hrs. Filtered the solid and washed the, cake with 100 cc n-heptane. Dried at 40-45°C under vacuum to get 85% amorphous form of (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxybenzyl)phenyl]-6- (hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol.
HPLC purity: 91-93%
Example 7: Preparation of amorphous form of (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4- ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
To the solid obtained from example 5 charged 500cc of n-heptane and stirred for ½ hrs at ambient temperature. Heated the reaction mass to 55-60°C and stirred it for 2-3 hrs., cooled to room temperature and maintained for 4-5 hrs. Filtered the solid and washed the cake with 100 cc n-heptane. Dried at 40-45 °C under vacuum to get 85-88% amorphous form of (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxybenzyl)phenyl]-6-
(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol.
HPLC purity: 89-91% Example 8: Preparation of L-proline - (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4- ethoxybenzyl)phenyI]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol co crystal
To the 10 cc of Ethyl acetate charged 1.0 mole (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4- ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol under argon atmosphere at ambient temperature and stirred for 30.0 min to get clear solution. Slowly heated the reaction mass to 60 - 65°C and stirred for 1 hr. Slowly added L-proline at 60 - 65°C and maintained for 1 hr. Slowly added 15 cc n-Heptane to the reaction mass at 60 - 65°C and stirred the mass for 2.5 hrs. Cooled the mass to ambient temperature for 3-4 hrs and maintained for 5 hrs. Filtered the mass under argon atmosphere. Washed the cake with 10 cc n-Heptane. Dried the cake at 50-55°C under reduced pressure to get 92% titled compound.
HPLC purity: 99%
Example 9: Preparation of L-proline - (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4- ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triolco crystal
To the 10 cc of acetone charged 1.0 mole (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4- ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol under argon atmosphere at ambient temperature and stirred for 30.0 min to get clear solution. Slowly heated the reaction mass to 60 - 65°C and stirred for 1 hr. Slowly added" proline at 60 - 65°C and maintained for 1 hr. Slowly added 15 cc n-Heptane to the reaction mass at 60 - 65°C and stirred the mass for 2.5 hrs. Cooled the mass to ambient temperature for 3-4 hrs and maintained for 5 hrs. Filtered the mass under argon atmosphere. Washed the cake with 10 cc n-Heptane. Dried the cake at 50-55°C under reduced pressure to get 93-95% titled compound.
HPLC purity: 98-99%
Example 10: Preparation of amorphous form of (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4- ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
To the 15 cc ethyl acetate added (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4- ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol at ambient temperature and stirred for 30.0 min. Slowly added 5- 8 cc sat. sodium bicarbonate solution at ambient temperature and stirred for 1.5 hr to get the clear solution. Settled down and separated layers. Extracted the aqueous layer with 25 cc ethyl acetate. Combined the organic layers and washed the ethyl acetate layer with 50 cc sat. Sodium chloride solution. Distilled out ethyl acetate under reduced pressure at 40 - 45°C to get ■fluffy solid. Charged 50 cc n-Heptane and stirred for 5 hrs to get 70-78% the title compound as Amorphous soild.
HPLC purity: 99.8-99.95 %
Example 11: Preparation of 2-chloro -4'- ethoxydiphenylmethane (impurity)
To the 20 cc THF and 20 cc Toluene added 0.25 mole 2-ehloro-5-bromo-4'- ethoxydiphenylmethane under argon atmosphere. Cooled the reaction mass to - 78° C. Slowly added n-Butyl lithium (1.9 M in hexane) at - 78° C and stirred for 30 min. Slowly added 20 % Ammonium chloride solution to the reaction mass. Brought the reaction mass to ambient temperature and stirred for 30 min. Settled and separated layers. Extracted the aqueous layer with 50 cc toluene. Washed the combined organic layer with 500 cc brine solution. Distilled out the toluene and charged heptanes, stirred for 2 - 3 hrs at ambient temperature. Filtered the product and dried the product at 45 - 50°C under reduced pressure to get 93 % titled compound.
Mass: (m+1) 247 m/z found 247.1 1
HPLC purity: 96.33 %

Claims

We claim,
1. A process for preparing (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4- ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5- triol(Formula-I) comprising
Figure imgf000021_0001
Formula-I
(a) Reacting 4-(5-bromo-2-chlorobenzyl)phenyl ethyl ether with 3,4,5-Tris- trimethylsilanyloxy-6-trimethylsilanyloxymethyl-tetrahydro-pyran-2-one in presence of mixture of polar aprotic solvent and non-polar solvent, organolithiiim reagent, alkyl sulfonic acid, monohydric or unsaturated aliphatic alcohol;
(b) Bringing pH neutral to alkaline to isolate 2-R1-2-[4-chloro-3-(4-ethoxy-benzyl)- phenyl]-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol;
(c) Reacting 2-R1-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-hydroxymethyl- tetrahydro-pyran-3,4,5-triol with organosilane in presence of acid, mixture of non-polar solvent and polar aprotic solvent under argon atmosphere and
(d) Quenching with sat. sodium bicarbonate solution to isolate (2S,3R,4R,5S,6R)-2- [4-chloro-3-(4-ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro-2H-pyran- 3,4,5-triol.
2. The process according to claim 1, wherein the polar aprotic solvent is selected from the group consisting of acetonitrile, tetrahydrofuran, ethyl acetate, acetone, dimethylformamide and dimethyl sulfoxide.
3. The process according to claim 1, wherein the non-polar solvent is selected from the group consisting of Dichloromethane, Toluene, Hexane, 1,4-Dioxane, Chloroform, Diethyl ether and n-Heptane. .
4. The process according to claim 1, wherein the R1 is allyl or prop-2ynyl.
5. The process according to claim 1, wherein the organolithium reagent is alkyllithium reagents selected from the group consisting of n-butyl lithium, methyl lithium and t-butyl lithium.
6. The process according to claim 1, wherein the alkyl sulfonic acid is methane sulfonic acid.
7. The process according to claim 1, wherein the unsaturated aliphatic alcohol is selected from the group consisting of allyl alcohol or propargyl alcohol.
8. The process according to claim 1, wherein the acid is selected from the group consisting of borontrifloride in diethylether, trifluoroacetic acid and methanesulfonic acid.
9. The process according to claim 1 , wherein the organosilane is alkylsilane or polyalkylsilane selected from the group consisting of trimethylsilane, triethylsilane, tetramethylsilane and dimethylsilane.
10. The process according to claim 1, wherein the reaction temperature for step (a) and (e) is -70 to -80 °C and -40 to -55 °C respectively.
11. A process for preparing amorphous form of (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4- ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol comprising
(a) Stirring (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxybenzyl)phenyl]-6- (hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol with non-polar solvent at ambient temperature and
(b) Isolating stable amorphous form of (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4- ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol. '
12. The process according to claim 11, wherein the non-polar solvent is n-heptane.
13. A process for preparing L-prolin complex of (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4- ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol comprising
(a) Reacting (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxybenzyl)phenyl]-6- (hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol with L-proline in presence of polar aprotic solvent under argon atmosphere;
(b) Adding non-polar solvent and
(c) Isolating L-prdline complex of (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4- ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol.
14. The process according to claim 13, wherein the polar aprotic solvent is ethyl acetate and non-polar solvent is n-Heptane.
15. The process according to any of the preceding claims, wherein the purity of (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxybenzyl)phenyl]-6- (hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol and L-prolin complex of (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxybenzyl)phenyl]-6- (hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol is 99.8-99.9 % and 98-99% respectively.
16. The compound, 2-R1-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-hydroxymethyl- tetrahydro-pyran-3,4,5-trio
Figure imgf000023_0001
Formula-V.
17. The compound according to claim 16 is selected from the group consisting of
(a) 2-Allyloxy-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-hydroxymethyl-tetrahydro- pyran-3,4,5-triol and
(b) 2-prop-2ynyl-2-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-6-hydroxymethyl- tetrahydro-pyran-3,4,5-triol.
18. A process for preparing des-bromo impurity, (2-chloro —4'- ethoxydiphenylmethane) (formula-VI) which comprises;
Figure imgf000023_0002
Formula-VI
(a) Reacting 2-chloro-5-bromo-4'-ethoxydiphenylmethane with alkyllithium in presence of mixture of polar aprotic solvent and non-polar solvent;
(b) Adding ammonium chloride solution and
(c) Isolating 2-chloro -4'- ethoxydiphenylmethane.
19. The process according to claim 18, wherein the alkyllithium reagent is selected from the group consisting of n-butyl lithium, methyl lithium and t-butyl lithium.
20. The process according to claim 18, wherein the non-polar solvent is selected from the group consisting of Dichloromethane, Toluene, Hexane, 1,4-dioxane, Chloroform, Diethyl ether and n-Heptane.
21. The process according to claim 18, wherein the polar aprotic solvent is selected from the group consisting of acetonitrile, tetrahydrofufan, ethyl acetate, acetone, dimethylformamide and dimethylsulfoxide.
22. The process according to claim 18, wherein the reaction temperature is -70 to -80
PCT/IN2015/000334 2015-03-17 2015-08-24 A novel process for preparing (2s,3r,4r,5s,6r)-2-[4-chloro-3-(4-ethoxybenzyl)pheny 1] -6-(hy droxy methyl)tetrahydro-2h-py ran-3,4,5-triol and its amorphous form WO2016147197A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN875MU2015 2015-03-17
IN875/MUM/2015 2015-03-17

Publications (1)

Publication Number Publication Date
WO2016147197A1 true WO2016147197A1 (en) 2016-09-22

Family

ID=56918428

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2015/000334 WO2016147197A1 (en) 2015-03-17 2015-08-24 A novel process for preparing (2s,3r,4r,5s,6r)-2-[4-chloro-3-(4-ethoxybenzyl)pheny 1] -6-(hy droxy methyl)tetrahydro-2h-py ran-3,4,5-triol and its amorphous form

Country Status (1)

Country Link
WO (1) WO2016147197A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107488156A (en) * 2017-09-04 2017-12-19 上海现代制药股份有限公司 A kind of synthetic method of unformed glucitol
CN108084130A (en) * 2017-12-15 2018-05-29 东南大学 A kind of preparation method of antidiabetic drug Dapagliflozin
WO2018124497A1 (en) * 2016-12-30 2018-07-05 한미약품 주식회사 Pharmaceutical composite preparation containing dapagliflozin l-proline and antidiabetic agent
WO2018097570A3 (en) * 2016-11-24 2018-08-09 한미약품 주식회사 Pharmaceutical formulation comprising dapagliflozin l-proline
WO2021176096A1 (en) 2020-03-05 2021-09-10 Krka, D.D., Novo Mesto Pharmaceutical composition comprising sglt2 inhibitor
CN113979978A (en) * 2021-03-31 2022-01-28 浙江美诺华药物化学有限公司 Preparation method of dapagliflozin

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040138439A1 (en) * 2003-01-03 2004-07-15 Deshpande Prashant P. Methods of producing C-aryl glucoside SGLT2 inhibitors
WO2008002824A1 (en) * 2006-06-28 2008-01-03 Bristol-Myers Squibb Company Crystalline solvates and complexes of (is) -1, 5-anhydro-l-c- (3- ( (phenyl) methyl) phenyl) -d-glucitol derivatives with amino acids as sglt2 inhibitors for the treatment of diabetes
WO2013064909A2 (en) * 2011-10-31 2013-05-10 Scinopharm Taiwan, Ltd. Crystalline and non-crystalline forms of sglt2 inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040138439A1 (en) * 2003-01-03 2004-07-15 Deshpande Prashant P. Methods of producing C-aryl glucoside SGLT2 inhibitors
WO2008002824A1 (en) * 2006-06-28 2008-01-03 Bristol-Myers Squibb Company Crystalline solvates and complexes of (is) -1, 5-anhydro-l-c- (3- ( (phenyl) methyl) phenyl) -d-glucitol derivatives with amino acids as sglt2 inhibitors for the treatment of diabetes
WO2013064909A2 (en) * 2011-10-31 2013-05-10 Scinopharm Taiwan, Ltd. Crystalline and non-crystalline forms of sglt2 inhibitors

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018097570A3 (en) * 2016-11-24 2018-08-09 한미약품 주식회사 Pharmaceutical formulation comprising dapagliflozin l-proline
WO2018124497A1 (en) * 2016-12-30 2018-07-05 한미약품 주식회사 Pharmaceutical composite preparation containing dapagliflozin l-proline and antidiabetic agent
CN107488156A (en) * 2017-09-04 2017-12-19 上海现代制药股份有限公司 A kind of synthetic method of unformed glucitol
CN108084130A (en) * 2017-12-15 2018-05-29 东南大学 A kind of preparation method of antidiabetic drug Dapagliflozin
WO2021176096A1 (en) 2020-03-05 2021-09-10 Krka, D.D., Novo Mesto Pharmaceutical composition comprising sglt2 inhibitor
CN113979978A (en) * 2021-03-31 2022-01-28 浙江美诺华药物化学有限公司 Preparation method of dapagliflozin

Similar Documents

Publication Publication Date Title
WO2016147197A1 (en) A novel process for preparing (2s,3r,4r,5s,6r)-2-[4-chloro-3-(4-ethoxybenzyl)pheny 1] -6-(hy droxy methyl)tetrahydro-2h-py ran-3,4,5-triol and its amorphous form
JP2007530687A5 (en)
EP2594569B1 (en) Entecavir synthesis method and intermediate compound thereof
JP5998198B2 (en) Regioselective acylation at position C-42 of rapamycin
CZ290093A3 (en) Hexahydronaphthalene ester derivatives, process of their preparation and pharmaceutical preparations in which they are comprised
AU2011218500A1 (en) Process for preparing entecavir and its intermediates
US6930187B2 (en) Method of preparation of 21-amino epothilone derivatives
US8258299B2 (en) Process for preparation of temsirolimus
WO2007049295A2 (en) An improved one pot process for making key intermediate for gemcitabine hcl
KR20140128392A (en) Methods and intermediates for preparing pharmaceutical agents
US10981939B2 (en) Process for the preparation of 4-[(1-hydroxy-1,3-dihydro-2,1-benzoxaborol-5-yl) oxy] benzonitrile (Crisaborole)
EP0167154B1 (en) Process for preparing 4-acetoxy-3-hydroxyethylazetizin-2-one derivatives
WO2016142950A1 (en) A novel process for preparing (2s,3r,4r,5s,6r)-2-{3-[5-[4-fluoro-phenyl)- thiophen-2-ylmethyl]-4-methyl-phenyl}-6-hydroxymethyl-tetrahydro-pyran-3,4,5- triol and its stable amorphous hemihydrate form
EP2655373A1 (en) Preparation process of an antiviral drug (entecavir) and intermediates thereof
WO2017060925A1 (en) Novel pipecolic acid co-crystals of dapagliflozin and process for the preparation thereof
EP3405463A1 (en) Process for the preparation of sofosbuvir
Dondoni et al. Regio-and stereoselective conjugate addition of nitrogen nucleophiles to 2-alkenyl n-methylthiazolium iodides. synthesis of d-3-epi-daunosamine and some lincosamine analogues
EP2227478A1 (en) Process and intermediates for the preparation of substituted 1, 3-oxathiolanes, especially lamivudine
KR20070108188A (en) Method for preparing docetaxel
US6509479B1 (en) Process for the removal of a silyloxy protecting group from 4-silyloxy-tetrahydro-pyran-2-ones
EP2643326B1 (en) Process for the preparation of (3R, 3aS, 6aR)-hexahydrofuro[2,3-b]furan-3-ol
EP3521293B1 (en) Process for the preparation of an inhibitor of phosphodiesterase 4
WO2017060924A1 (en) A novel pipecolic acid co-crystal of canagliflozin and process for the preparation thereof
EP0801057B1 (en) Process for producing optically active trans-vinyl sulfide alcohols
CN107488190B (en) Ezetimibe intermediate and preparation method thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15885309

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15885309

Country of ref document: EP

Kind code of ref document: A1